SABCS 2025 Session Makes Sense of Rapidly Evolving Therapeutic Landscape for Breast Cancer
At the SABCS 2025 View From the Trenches session, experts discussed how new clinical trial results might transform breast cancer care.
Progress Against Cancer
At the SABCS 2025 View From the Trenches session, experts discussed how new clinical trial results might transform breast cancer care.
Proton therapy for oropharyngeal cancer increases overall survival, and risk-based screening for breast cancer appears to be as effective as annual screening.
A year-end review of some of the new cancer treatments, exciting breakthroughs, and insights into cancer's development that emerged in 2025.
Patients now have the option of receiving the bispecific antibody amivantamab as an injection. The U.S. Food and Drug Administration (FDA) has approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for subcutaneous injection as an alternative...
Fam-trastuzumab deruxtecan-nxki (T-DXd) with pertuzumab was approved to treat metastatic HER2-positive breast cancer. The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for patients with...
Clinical trial presented at SABCS finds some patients may safely skip sentinel lymph node biopsy.
In clinical trials presented at SABCS, a mobile health tool and acupuncture helped to improve breast cancer survivors' quality of life.
The addition of targeted therapy helps control metastatic breast cancer, and a pair of immunotherapy drugs prolongs survival in multiple myeloma.
Amid the debate over menopausal hormone therapy and cancer risk, researchers at SABCS provided some clarity for women with BRCA1/2 mutations.
SABCS educational session highlights how alcohol and obesity can raise the risk for breast cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More